Regulation of PD-L1: A novel role of pro-survival signalling in cancer

Annals of Oncology

Volumn 27, Issue 3, 2016, Pages 409-416

  Chen, J ^a,b   Jiang, C C ^c   Jin, L ^c   Zhang, Xu D ^a  

^a NEWCASTLE UNIVERSITY   (United Kingdom)

^b UNIVERSITY OF QUEENSLAND   (Australia)

^c NEWCASTLE UNIVERSITY   (United Kingdom)

Author keywords

Akt; HIF 1ANHMRC projectAPP1083496; immune checkpoint; MAPK; NF B; STAT3

Indexed keywords

BIOLOGICAL MARKER; HYPOXIA INDUCIBLE FACTOR 1ALPHA; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; MICRORNA; MICRORNA 197; MICRORNA 200; MICRORNA 34A; MICRORNA 513; MICRORNA 570; MITOGEN ACTIVATED PROTEIN KINASE; PHOSPHATIDYLINOSITOL 3 KINASE; PROGRAMMED DEATH 1 LIGAND 1; PROTEIN KINASE B; PROTEIN TYROSINE PHOSPHATASE SHP 1; PROTEIN TYROSINE PHOSPHATASE SHP 2; STAT3 PROTEIN; T LYMPHOCYTE RECEPTOR; UNCLASSIFIED DRUG; CD274 PROTEIN, HUMAN; PDCD1 PROTEIN, HUMAN; PROGRAMMED DEATH 1 RECEPTOR; PROTEIN BINDING; STAT3 PROTEIN, HUMAN; TUMOR MARKER;

ANTIGEN PRESENTING CELL; CANCER CELL; CANCER PROGNOSIS; CANCER SURVIVAL; CARCINOGENESIS; CD274 GENE; CELL PROLIFERATION; DENDRITIC CELL; ENZYME ACTIVATION; ENZYME ACTIVITY; ENZYME INHIBITION; ENZYME REGULATION; EPIGENETICS; GENE; HUMAN; IMMUNE SYSTEM; LYMPHOCYTE PROLIFERATION; MACROPHAGE; MALIGNANT NEOPLASTIC DISEASE; MONOCYTE; NONHUMAN; PDCD1 GENE; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN PROTEIN INTERACTION; PROTEIN TARGETING; REVIEW; SIGNAL TRANSDUCTION; T LYMPHOCYTE ACTIVATION; TRANSCRIPTION REGULATION; UPREGULATION; B LYMPHOCYTE; GENETICS; IMMUNOLOGY; METABOLISM; NATURAL KILLER T CELL; NEOPLASM; PROMOTER REGION; T LYMPHOCYTE; TUMOR ESCAPE;

ANTIGENS, CD274; B-LYMPHOCYTES; BIOMARKERS, TUMOR; CELL PROLIFERATION; DENDRITIC CELLS; HUMANS; HYPOXIA-INDUCIBLE FACTOR 1, ALPHA SUBUNIT; MICRORNAS; MITOGEN-ACTIVATED PROTEIN KINASES; NATURAL KILLER T-CELLS; NEOPLASMS; NF-KAPPA B; PHOSPHATIDYLINOSITOL 3-KINASES; PROGRAMMED CELL DEATH 1 RECEPTOR; PROMOTER REGIONS, GENETIC; PROTEIN BINDING; SIGNAL TRANSDUCTION; STAT3 TRANSCRIPTION FACTOR; T-LYMPHOCYTES; TUMOR ESCAPE;

EID: 84959865627     PISSN: 09237534     EISSN: 15698041     Source Type: Journal    
DOI: 10.1093/annonc/mdv615     Document Type: Review

References (98)

1. Restifo NP, Dudley ME, Rosenberg SA. Adoptive immunotherapy for cancer: harnessing the T cell response. Nat Rev Immunol 2012; 12: 269-281.
2. Mellman I, Coukos G, DranoffG. Cancer immunotherapy comes of age. Nature 2011; 480: 480-489.
3. Lake RA, Robinson BW. Immunotherapy and chemotherapy-a practical partnership. Nat Rev Cancer 2005; 5: 397-405.
4. Rosenberg SA, Restifo NP, Yang JC et al. Adoptive cell transfer: a clinical path to effective cancer immunotherapy. Nat Rev Cancer 2008; 8: 299-308.
5. KantoffPW, Higano CS, Shore ND et al. Sipuleucel-T immunotherapy for castration-resistant prostate cancer. N Engl J Med 2010; 363: 411-422.
6. Rosenberg SA. Cell transfer immunotherapy for metastatic solid cancer-what clinicians need to know. Nat Rev Clin Oncol 2011; 8: 577-585.
7. Palucka K, Banchereau J. Cancer immunotherapy via dendritic cells. Nat Rev Cancer 2012; 12: 265-277.
8. Kochenderfer JN, Rosenberg SA. Treating B-cell cancer with T cells expressing anti-CD19 chimeric antigen receptors. Nat Rev Clin Oncol 2013; 10: 267-276.
9. Cheadle EJ, Gornall H, Baldan V et al. CAR T cells: driving the road from the laboratory to the clinic. Immunol Rev 2014; 257: 91-106.
10. La-Beck NM, Jean GW, Huynh C et al. Immune checkpoint inhibitors: new insights and current place in cancer therapy. Pharmacotherapy 2015; 35: 963-976.
11. Brahmer JR, Tykodi SS, Chow LQ et al. Safety and activity of anti-PD-L1 antibody in patients with advanced cancer. N Engl J Med 2012; 366: 2455-2465.
12. Topalian SL, Hodi FS, Brahmer JR et al. Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. N Engl J Med 2012; 366: 2443-2454.
13. Pardoll DM. The blockade of immune checkpoints in cancer immunotherapy. Nat Rev Cancer 2012; 12: 252-264.
14. Wolchok JD, Kluger H, Callahan MK et al. Nivolumab plus ipilimumab in advanced melanoma. N Engl J Med 2013; 369: 122-133.
15. Jiang X, Zhou J, Giobbie-Hurder A et al. The activation of MAPK in melanoma cells resistant to BRAF inhibition promotes PD-L1 expression that is reversible by MEK and PI3K inhibition. Clin Cancer Res 2013; 19: 598-609.
16. Mittendorf EA, Philips AV, Meric-Bernstam F et al. PD-L1 expression in triple negative breast cancer. Cancer Immunol Res 2014; canimm. 0127.2013.
17. Song M, Chen D, Lu B et al. PTEN loss increases PD-L1 protein expression and affects the correlation between PD-L1 expression and clinical parameters in colorectal cancer. PLoS One 2013; 8: e65821.
18. Chen L. Co-inhibitory molecules of the B7-CD28 family in the control of T-cell immunity. Nat Rev Immunol 2004; 4: 336-347.
19. Ishida Y, Agata Y, Shibahara K, Honjo T. Induced expression of PD-1, a novel member of the immunoglobulin gene superfamily, upon programmed cell death. EMBO J 1992; 11: 3887.
20. Ahmadzadeh M, Johnson LA, Heemskerk B et al. Tumor antigen-specific CD8T cells infiltrating the tumor express high levels of PD-1 and are functionally impaired. Blood 2009; 114: 1537-1544.
21. Weber J. Immune checkpoint proteins: a new therapeutic paradigm for cancer-preclinical background: CTLA-4 and PD-1 blockade. Semin Oncol 2010; 430-439.
22. Blackburn SD, Crawford A, Shin H et al. Tissue-specific differences in PD-1 and PD-L1 expression during chronic viral infection: implications for CD8 T-cell exhaustion. J Virol 2010; 84: 2078-2089.
23. Linsley PS, Greene JL, Brady W et al. Human B7-1 (CD80) and B7-2 (CD86) bind with similar avidities but distinct kinetics to CD28 and CTLA-4 receptors. Immunity 1994; 1: 793-801.
24. Nishimura H, Nose M, Hiai H et al. Development of lupus-like autoimmune diseases by disruption of the PD-1 gene encoding an ITIM motif-carrying immunoreceptor. Immunity 1999; 11: 141-151.
25. Zhang X, Schwartz J-CD, Guo X et al. Structural and functional analysis of the costimulatory receptor programmed death-1. Immunity 2004; 20: 337-347.
26. Keir ME, Butte MJ, Freeman GJ, Sharpe AH. PD-1 and its ligands in tolerance and immunity. Annu Rev Immunol 2008; 26: 677-704.
27. Freeman GJ, Long AJ, Iwai Y et al. Engagement of the PD-1 immunoinhibitory receptor by a novel B7 family member leads to negative regulation of lymphocyte activation. J Exp Med 2000; 192: 1027-1034.
28. Latchman Y, Wood CR, Chernova T et al. PD-L2 is a second ligand for PD-1 and inhibits T cell activation. Nat Immunol 2001; 2: 261-268.
29. Sharpe AH, Wherry EJ, Ahmed R, Freeman GJ. The function of programmed cell death 1 and its ligands in regulating autoimmunity and infection. Nat Immunol 2007; 8: 239-245.
30. Dong H, Zhu G, Tamada K, Chen L. B7-H1, a third member of the B7 family, costimulates T-cell proliferation and interleukin-10 secretion. Nat Med 1999; 5: 1365-1369.
31. Shi L, Chen S, Yang L, Li Y. The role of PD-1 and PD-L1 in T-cell immune suppression in patients with hematological malignancies. J Hematol Oncol 2013; 6: 74.
32. Topalian SL, Drake CG, Pardoll DM. Targeting the PD-1/B7-H1 (PD-L1) pathway to activate anti-tumor immunity. Curr Opin Immunol 2012; 24: 207-212.
33. Francisco LM, Salinas VH, Brown KE et al. PD-L1 regulates the development, maintenance, and function of induced regulatory T cells. J Exp Med 2009; 206: 3015-3029.
34. Chen Y, Wang Q, Shi B et al. Development of a sandwich ELISA for evaluating soluble PD-L1 (CD274) in human sera of different ages as well as supernatants of PD-L1+ cell lines. Cytokine 2011; 56: 231-238.
35. Rossille D, Gressier M, Damotte D et al. High level of soluble programmed cell death ligand 1 in blood impacts overall survival in aggressive diffuse large B-Cell lymphoma: results from a French multicenter clinical trial. Leukemia 2014; 28: 2367-2375.
36. Junjun C, Hongbing S, Xiao Z et al. Detection of soluble B7-H4 molecules in serum of patients with breast cancer and its clinical significance. J Int Transl Med 2013; 1: 215-218.
37. Herbst RS, Soria J-C, Kowanetz M et al. Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients. Nature 2014; 515: 563-567.
38. Gao Q, Wang X-Y, Qiu S-J et al. Overexpression of PD-L1 significantly associates with tumor aggressiveness and postoperative recurrence in human hepatocellular carcinoma. Clin Cancer Res 2009; 15: 971-979.
39. Hamanishi J, Mandai M, Iwasaki M et al. Programmed cell death 1 ligand 1 and tumor-infiltrating CD8+ T lymphocytes are prognostic factors of human ovarian cancer. Proc Natl Acad Sci USA 2007; 104: 3360-3365.
40. Spranger S, Spaapen RM, Zha Y et al. Up-regulation of PD-L1, IDO, and Tregs in the melanoma tumor microenvironment is driven by CD8+ T cells. Sci Transl Med 2013; 5: 200ra116-200ra116.
41. Massi D, Brusa D, Merelli B et al. The status of PD-L1 and tumor-infiltrating immune cells predict resistance and poor prognosis in BRAFi-treated melanoma patients harboring mutant BRAFV600. Ann Oncol 2015; 26: 1980-1987.
42. Massi D, Brusa D, Merelli B et al. PD-L1 marks a subset of melanomas with a shorter overall survival and distinct genetic and morphological characteristics. Ann Oncol 2014; 25: 2433-2442.
43. Abiko K, Mandai M, Hamanishi J et al. PD-L1 on tumor cells is induced in ascites and promotes peritoneal dissemination of ovarian cancer through CTL dysfunction. Clin Cancer Res 2013; 19: 1363-1374.
44. Wang L, Liu H, Chen X et al. Immune sculpting of norepinephrine on MHC-I, B7-1, IDO and B7-H1 expression and regulation of proliferation and invasion in pancreatic carcinoma cells. Plos One 2012; 7(e45491): 1-11.
45. Chen L, Gibbons DL, Goswami S et al. Metastasis is regulated via microRNA-200/ZEB1 axis control of tumour cell PD-L1 expression and intratumoral immunosuppression. Nat Commun 2014; 5(article 5241): 1-12.
46. Alsuliman A, Colak D, Al-Harazi O et al. Bidirectional crosstalk between PD-L1 expression and epithelial to mesenchymal transition: Significance in claudin-low breast cancer cells. Mol Cancer 2015; 14: 1.
47. Fang JY, Richardson BC. The MAPK signalling pathways and colorectal cancer. Lancet Oncol 2005; 6: 322-327.
48. Downward J. Targeting RAS signalling pathways in cancer therapy. Nat Rev Cancer 2003; 3: 11-22.
49. Dhillon A, Hagan S, Rath O, Kolch W. MAP kinase signalling pathways in cancer. Oncogene 2007; 26: 3279-3290.
50. Davies H, Bignell GR, Cox C et al. Mutations of the BRAF gene in human cancer. Nature 2002; 417: 949-954.
51. Sumimoto H, Imabayashi F, Iwata T, Kawakami Y. The BRAF-MAPK signaling pathway is essential for cancer-immune evasion in human melanoma cells. J Exp Med 2006; 203: 1651-1656.
52. Borre PV, Gunda V, McFadden DG et al. Combined BRAFV600E-and SRCinhibition induces apoptosis, evokes an immune response and reduces tumor growth in an immunocompetent orthotopic mouse model of anaplastic thyroid cancer. Oncotarget 2014; 5: 3996.
53. Chen N, Fang W, Zhan J et al. Up-regulation of PD-L1 by EGFR Activation Mediates the Immune Escape in EGFR-driven NSCLC: Implication for Optional Immune Targeted Therapy for NSCLC Patients with EGFR Mutation. J Thorac Oncol 2015; 10: 910-923.
54. Landsberg J, Gaffal E, Cron M et al. Autochthonous primary and metastatic melanomas in Hgf-Cdk4R24C mice evade T-cell-mediated immune surveillance. Pigment Cell Melanoma Res 2010; 23: 649-660.
55. Balan M, Teran EMY, Waaga-Gasser AM et al. Novel Roles of c-Met in the Survival of Renal Cancer Cells through the Regulation of HO-1 and PD-L1 Expression. J Biol Chem 2015; 290: 8110-8120.
56. Gong W, Song Q, Lu X et al. Paclitaxel Induced B7-H1 Expression in Cancer Cells via the MAPK Pathway. J Chemother 2011; 23: 295-299.
57. Qin X, Liu C, Zhou Y, Wang G. Cisplatin induces programmed death-1-ligand 1 (PD-L1) over-expression in hepatoma H22 cells via Erk/MAPK signaling pathway. Cell Mol Biol (Noisy-le-grand) 2009; 56: OL1366-OL1372.
58. Franke TF, Kaplan DR, Cantley LC. PI3K: downstream AKTion blocks apoptosis. Cell 1997; 88: 435-437.
59. Vivanco I, Sawyers CL. The phosphatidylinositol 3-kinase-AKT pathway in human cancer. Nat Rev Cancer 2002; 2: 489-501.
60. Chen J. Signaling pathways in HPV-associated cancers and therapeutic implications. Rev Med Virol 2015; 25: 24-53.
61. Chen J, Zhang XD, Proud C. Dissecting the signaling pathways that mediate cancer in PTEN and LKB1 double-knockout mice. Sci Signal 2015; 8(pe1): 1-3.
62. Ye Y, Jin L, Wilmott JS et al. PI (4, 5) P2 5-phosphatase A regulates PI3K/Akt signalling and has a tumour suppressive role in human melanoma. Nat commun 2013; 4: 1508.
63. Schurmans S, Roger PP, Erneux C. SHIP2 signaling in normal and pathological situations: its impact on cell proliferation. Adv Biol Regul 2014; 54: 142-151.
64. Cheng H, Liu P, Zhang F et al. A genetic mouse model of invasive endometrial cancer driven by concurrent loss of Pten and Lkb1 Is highly responsive to mTOR inhibition. Cancer Res 2014; 74: 15-23.
65. Gowrishankar K, Gunatilake D, Gallagher SJ et al. Inducible but not constitutive expression of PD-L1 in human melanoma cells is dependent on activation of NF-κB. Plos One 2015; 10(e0123410): 1-19.
66. Pollizzi KN, Powell JD. Integrating canonical and metabolic signalling programmes in the regulation of T cell responses. Nat Rev Immunol 2014; 14: 435-446.
67. Pawelec G, Derhovanessian E, Larbi A. Immunosenescence and cancer. Crit Rev Oncol Hematol 2010; 75: 165-172.
68. Barsoum IB, Koti M, Siemens DR, Graham CH. Mechanisms of hypoxia-mediated immune escape in cancer. Cancer Res 2014; 74: 7185-7190.
69. Shehade H, Oldenhove G, Moser M. Hypoxia in the intestine or solid tumors: A beneficial or deleterious alarm signal? Eur J Immunol 2014; 44: 2550-2557.
70. Barsoum IB, Smallwood CA, Siemens DR, Graham CH. A mechanism of hypoxiamediated escape from adaptive immunity in cancer cells. Cancer Res 2014; 74: 665-674.
71. Noman MZ, Desantis G, Janji B et al. PD-L1 is a novel direct target of HIF-1a, and its blockade under hypoxia enhanced MDSC-mediated T cell activation. J Exp Med 2014; 211: 781-790.
72. Ortmann B, Druker J, Rocha S. Cell cycle progression in response to oxygen levels. Cell Mol Life Sci 2014; 71: 3569-3582.
73. Brown JM, Wilson WR. Exploiting tumour hypoxia in cancer treatment. Nat Rev Cancer 2004; 4: 437-447.
74. Wilson WR, Hay MP. Targeting hypoxia in cancer therapy. Nat Rev Cancer 2011; 11: 393-410.
75. Vaupel P, Mayer A. Hypoxia in cancer: significance and impact on clinical outcome. Cancer Metastasis Rev 2007; 26: 225-239.
76. Noman MZ, Chouaib S. Targeting hypoxia at the forefront of anticancer immune responses. OncoImmunology 2014; 3(e954463): 1-3.
77. Marzec M, Zhang Q, Goradia A et al. Oncogenic kinase NPM/ALK induces through STAT3 expression of immunosuppressive protein CD274 (PD-L1, B7-H1). Proc Natl Acad Sci USA 2008; 105: 20852-20857.
78. Fang W, Zhang J, Hong S et al. EBV-driven LMP1 and IFN-γ up-regulate PD-L1 in nasopharyngeal carcinoma: Implications for oncotargeted therapy. Oncotarget 2014; 5: 12189-12202.
79. Bartel DP. MicroRNAs: target recognition and regulatory functions. Cell 2009; 136: 215-233.
80. Wrangle J, Wang W, Koch A et al. Alterations of immune response of non-small cell lung cancer with azacytidine. Oncotarget 2013; 4: 2067.
81. Chen X-M. MicroRNA signatures in liver diseases. World J Gastroenterol 2009; 15: 1665.
82. Wang X, Li J, Dong K et al. Tumor suppressor miR-34a targets PD-L1 and functions as a potential immunotherapeutic target in acute myeloid leukemia. Cell Signal 2015; 27: 443-452.
83. Gong A-Y, Zhou R, Hu G et al. Cryptosporidium parvum induces B7-H1 expression in cholangiocytes by down-regulating microRNA-513. J Infect Dis 2010; 201: 160-169.
84. Jardim MJ, Fry RC, Jaspers I et al. Disruption of microRNA expression in human airway cells by diesel exhaust particles is linked to tumorigenesis-associated pathways. Environ Health Perspect 2009; 117: 1745-1751.
85. Wang W, Li F, Mao Y et al. A miR-570 binding site polymorphism in the B7-H1 gene is associated with the risk of gastric adenocarcinoma. Hum Genet 2013; 132: 641-648.
86. Fujita Y, Yagishita S, Hagiwara K et al. The clinical relevance of the miR-197/CKS1B/STAT3-mediated PD-L1 network in chemoresistant non-small-cell lung cancer. Mol Ther 2015; 23: 717-727.
87. Chen J. Multiple signal pathways in obesity-associated cancer. Obes Rev 2011; 12: 1063-1070.
88. Yu H, Pardoll D, Jove R. STATs in cancer inflammation and immunity: a leading role for STAT3. Nat Rev Cancer 2009; 9: 798-809.
89. Hino R, Kabashima K, Kato Y et al. Tumor cell expression of programmed cell death-1 ligand 1 is a prognostic factor for malignant melanoma. Cancer 2010; 116: 1757-1766.
90. Mu C-Y, Huang J-A, Chen Y et al. High expression of PD-L1 in lung cancer may contribute to poor prognosis and tumor cells immune escape through suppressing tumor infiltrating dendritic cells maturation. Med Oncol 2011; 28: 682-688.
91. Thompson RH, Kuntz SM, Leibovich BC et al. Tumor B7-H1 is associated with poor prognosis in renal cell carcinoma patients with long-term follow-up. Cancer Res 2006; 66: 3381-3385.
92. Hsu M-C, Hsiao J-R, Chang K-C et al. Increase of programmed death-1-expressing intratumoral CD8T cells predicts a poor prognosis for nasopharyngeal carcinoma. Mod Pathol 2010; 23: 1393-1403.
93. Lin C, Li M, Liu J et al. PD-L1 expression predicts tyrosine kinase inhibitor response and better prognosis in a cohort of patients with EGFR mutation-positive lung adenocarcinoma. Clin Lung Cancer 2015; 16: e25-e35.
94. Velcheti V, Schalper KA, Carvajal DE et al. Programmed death ligand-1 expression in non-small cell lung cancer. Lab Invest 2014; 94: 107-116.
95. Solit DB, Rosen N. Resistance to BRAF inhibition in melanomas. N Engl J Med 2011; 364: 772.
96. Queirolo P, Picasso V, Spagnolo F. Combined BRAF and MEK inhibition for the treatment of BRAF-mutated metastatic melanoma. Cancer Treat Rev 2015; 41: 519-526.
97. Vanneman M, DranoffG. Combining immunotherapy and targeted therapies in cancer treatment. Nat Rev Cancer 2012; 12: 237-251.
98. Liu L, Mayes PA, Eastman S et al. The BRAF and MEK Inhibitors Dabrafenib and Trametinib: Effects on Immune Function and in Combination with Immunomodulatory Antibodies Targeting PD1, PD-L1 and CTLA-4. Clin Cancer Res 2015: 21: 1639-1651.